SEC Comment Letter for Protalix BioTherapeutics, Inc. (PLX) (CIK 0001006281) (PLX) — Mar 23, 2009

Protalix BioTherapeutics, Inc. (PLX) (CIK 0001006281)
Date: March 23, 2009 · CIK: 0001006281 · Accession: 0000000000-09-014731

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-33357

Date

March 19, 2009

Author

Joel Parker

Form

UPLOAD

Company

Protalix BioTherapeutics, Inc. (PLX) (CIK 0001006281)

Letter

Via Facsimile and U.S. Mail Mail Stop 6010 March 19, 2009 Yossi Maimon Chief Financial Officer and Treasurer Protalix BioTherapeutics, Inc. 2 Snunit Street Science Park POB 455 Carmiel, Israel 20100

Re: Protalix BioTherapeutics Form 10-K for the Fiscal Year Ended December 31, 2007 Filed March 17, 2008 File Number: 001-33357

Dear Mr. Maimon:

We have completed our review of your Form 10-K and have no further comments at this time. S i n c e r e l y , Joel Parker A c c o u n t i n g B r a n c h C h i e f

Show Raw Text

Via Facsimile and U.S. Mail Mail Stop 6010                                                                                                  March 19, 2009
Yossi Maimon
Chief Financial Officer and Treasurer
Protalix BioTherapeutics, Inc.
2 Snunit Street
Science Park
POB 455
Carmiel, Israel 20100

Re:    Protalix BioTherapeutics
 Form 10-K for the Fiscal Year Ended December 31, 2007
 Filed March 17, 2008
 File Number:  001-33357

 Dear Mr. Maimon:

  We have completed our review of  your Form 10-K and have no further
comments at this time.            S i n c e r e l y ,
Joel Parker
        A c c o u n t i n g  B r a n c h  C h i e f

SecProbe.io